Regulatory Science

Regulatory science seeks to improve the evidence base for regulation of tobacco products and their marketing, including economic models that account for short-term and long-term effects of tobacco use, better understanding of behavioral determinants of tobacco use, and functional biomarkers of acute cardiopulmonary responses to tobacco use that could be used in premarket testing of tobacco products.
  • We are studying the effects of both active smoking and secondhand smoke exposure on susceptibility to acute lung injury, a major cause of respiratory failure among critically ill patients.

    Assistant Professor of Medicine
  • The absolute negative health burden from smoking is greatest for adults over age 55. Older adults (>45) are growing in number and are the least likely to quit of any age group, perhaps because they underestimate both the risks for smoking and the benefits of cessation.Older age is positively correlated with rationalizing beliefs about quitting smoking: older smokers exhibit greater unrealistic optimism about their risks for tobacco-related diseases and death than their younger counterparts.

    Associate Professor, Department of Physiological Nursing - Gerontology/Oncology
  • This Core serves two functions: (1) to provide a service to TCORS investigators by carrying out the analysis of biofluid samples for their studies and (2) to develop new biomarkers of exposure that can be applied to the studies carried out by TCORS investigators, as well as to advance the field.

    Professor of Medicine, Bioengineering and Therapeutic Sciences
  • We are investigating the addictive potential of e-cigarettes through assessment of nicotine pharmacokinetic parameters in clinical studies as well as e-cigarette features that affect nicotine delivery and toxic compound formation

    Assistant Professor of Medicine, Division of Clinical Pharmacology, Dept. of Medicine
  • Cigarette smoking continues to be a major cause of cardiovascular disease (CVD). In contrast, the cardiovascular risks of other tobacco products in common use (smokeless tobacco) and new tobacco products (e-cigarettes) are not adequately understood. The FDA will need information about the cardiovascular safety of these products to inform their regulatory decisions.

    Professor in Residence, Cardiology, San Francisco General Hospital
  • Unlike smoking,conventional smokeless tobacco (ST) (moist snuff, known as dip and chewing tobacco) among US high school students is much higher among males (13%) than females (2%) and is especially high in rural areas.  In 2005, ST manufacturers spent over $250 million on marketing, including “new” ST products such as dissolvable films, compressed tobacco (e.g.

    Professor, School of Dentistry
  • In the general public and most research communities, the primary health consequences of smoking are perceived to be cancer, cardiovascular disease, chronic pulmonary disease as well as acute pulmonary consequences of smoke exposure in the young and critically ill patients. However, comparatively little research has focused on the detrimental effects of chronic tobacco smoking on the human brain and on cognitive functioning.  The FDA needs information about the newly emerging cerebral (and cognitive) consequences of tobacco use to properly assume their regulatory responsibilities.

    UCSF Professor of Radiology and Biomedical Imaging
    Director, Substance Abuse Neuroimaging DVA Medical Center Center for Imaging of Neurodegenerative Diseases (CIND)
    Co-Director, San Francisco Treatment Research Center School of Medicine, UCSF